Search / Trial NCT06229626

Evaluation of an Intensive Training Program for Patients With Hereditary Spastic Paraparesis SPG4/Spast

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jan 19, 2024

Trial Information

Current as of October 08, 2024

Recruiting

Keywords

Physical Rehabilitation Program Hereditary Spastic Paraparesis

Description

Following an initial study carried out by the team (cf citation), physiotherapy appeared to be the most useful therapy for coping with spasticity, particularly when practised at least 3 times a week. The hypothesis is that this feeling experienced by patients is accurate, and that more frequent physiotherapy (3 additional sessions/week) significantly improves patients' walking speed, with a functional objective. The main aim of the WALK-UP study is to evaluate the efficacy of a 6-week intensive physical rehabilitation program on walking speed in patients with SPG4 / SPAST-HSP. This is the ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patient with molecular diagnosis of hereditary spastic paraparesis based on pathogenic variant of SPAST gene,
  • * Walking possible for 6 minutes without human assistance (one or more technical aids are authorized: e.g. cane, walker, orthoses),
  • * At least 1 physiotherapy session per week already in place.
  • * Understanding of the protocol
  • * Possibility of connecting to the Internet from home to access video material provided as part of the protocol.
  • Exclusion Criteria:
  • * Botulinum toxin injection within 4 months of protocol inclusion
  • * Discontinuation of private physiotherapy,
  • * Refusal to participate in the protocol,
  • * Participation in another interventional research study, or being in the exclusion period following a previous study, if applicable.
  • * Pregnant women
  • * Not affiliated to a social security scheme or beneficiary of such a scheme
  • * Patient under guardianship or trusteeship

About Assistance Publique Hôpitaux De Paris

Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.

Locations

Paris, , France

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0